Literature DB >> 16682845

The metabolic syndrome in polycystic ovary syndrome.

P A Essah1, J E Nestler.   

Abstract

Much overlap is present between the polycystic ovary syndrome (PCOS) and the metabolic syndrome. This article reviews the existing data regarding the prevalence, characteristics, and treatment of the metabolic syndrome in women with PCOS. The prevalence of the metabolic syndrome in PCOS is approximately 43-47%, a rate 2-fold higher than that for women in the general population. High body mass index and low serum HDL cholesterol are the most frequently occurring components of the metabolic syndrome in PCOS. The pathogenic link between the metabolic syndrome and PCOS is most likely insulin resistance. Therefore, the presence of the metabolic syndrome in PCOS suggests a greater degree of insulin resistance compared to PCOS without the metabolic syndrome. Obesity, atherogenic dyslipidemia, hypertension, impaired fasting glucose/impaired glucose tolerance, and vascular abnormalities are all common metabolic abnormalities present in PCOS. Lifestyle modification has proven benefit and pharmacological therapy with insulin-sensitizing agents has potential benefit in the treatment of the metabolic syndrome in women with PCOS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682845     DOI: 10.1007/BF03345554

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  74 in total

1.  The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.

Authors:  J J Conn; H S Jacobs; G S Conway
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

3.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

4.  Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.

Authors:  S Zimmermann; R A Phillips; A Dunaif; D T Finegood; C Wilkenfeld; M Ardeljan; R Gorlin; L R Krakoff
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

Review 5.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

6.  Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.

Authors:  Vicken Sepilian; Manubai Nagamani
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

Review 7.  Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome.

Authors:  Fleur R Cattrall; David L Healy
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2004-10       Impact factor: 5.237

8.  Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.

Authors:  Miriam E Silfen; Michelle R Denburg; Alexandra M Manibo; Rogerio A Lobo; Richard Jaffe; Michel Ferin; Lenore S Levine; Sharon E Oberfield
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones.

Authors:  E Dahlgren; S Johansson; G Lindstedt; F Knutsson; A Odén; P O Janson; L A Mattson; N Crona; P A Lundberg
Journal:  Fertil Steril       Date:  1992-03       Impact factor: 7.329

View more
  31 in total

1.  Defining the role of bariatric surgery in polycystic ovarian syndrome patients.

Authors:  Shaveta M Malik; Michael L Traub
Journal:  World J Diabetes       Date:  2012-04-15

Review 2.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Prenatal programming by testosterone of hypothalamic metabolic control neurones in the ewe.

Authors:  K M Sheppard; V Padmanabhan; L M Coolen; M N Lehman
Journal:  J Neuroendocrinol       Date:  2011-05       Impact factor: 3.627

4.  The relevance of inflammatory markers in metabolic syndrome.

Authors:  Genel Sur; Emanuela Floca; Liana Kudor-Szabadi; Maria Lucia Sur; Daniel Sur; Gabriel Samasca
Journal:  Maedica (Buchar)       Date:  2014-03

5.  Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome.

Authors:  S Savastano; R Valentino; G Pizza; A De Rosa; F Orio; F Passaretti; P Formisano; G Lombardi; F Beguinot; A Colao
Journal:  J Endocrinol Invest       Date:  2010 Jul-Aug       Impact factor: 4.256

6.  Gonadal dysfunction in morbidly obese adolescent girls.

Authors:  Vivian Chin; Marisa Censani; Shulamit Lerner; Rushika Conroy; Sharon Oberfield; Donald McMahon; Jeffrey Zitsman; Ilene Fennoy
Journal:  Fertil Steril       Date:  2014-02-26       Impact factor: 7.329

7.  Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females.

Authors:  V Padmanabhan; A Veiga-Lopez; D H Abbott; S E Recabarren; C Herkimer
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

8.  Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.

Authors:  A Priyadarshani
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

Review 9.  Developmental reprogramming of reproductive and metabolic dysfunction in sheep: native steroids vs. environmental steroid receptor modulators.

Authors:  V Padmanabhan; H N Sarma; M Savabieasfahani; T L Steckler; A Veiga-Lopez
Journal:  Int J Androl       Date:  2010-01-12

10.  The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients.

Authors:  M Erdogan; M Karadeniz; A Berdeli; G Alper; O Caglayan; C Yilmaz
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.